Skip to main content
. 2020 Feb 7;5:12. doi: 10.1038/s41392-019-0104-3

Fig. 4.

Fig. 4

The study of pharmacokinetics and biodistribution of C-DVM. The pharmacokinetics profiles of (a) D and (b) V after intravenous delivery. All data were presented as mean ± SD (n = 5). c Doxorubicin accumulation in major organs in DOX, D + V, DVM, and C-DVM treatment groups, measured by doxorubicin fluorescence. d Quantification of the fluorescence radiance from c. All data were presented as mean ± SD (n = 5), **P < 0.01, ***P < 0.005